Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1050 of 2026 entries
View as:

Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

Phase: N/A Priority: Normal
NCT ID: NCT02515669 Org: User:
Start: 12/02/15 End: 04/15/20 Due: 04/15/21

A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01615354 Org: User:
Start: 07/31/12 End: 01/31/13 Due: 01/31/14

A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

Phase: N/A Priority: Normal
NCT ID: NCT01183858 Org: User:
Start: 10/31/10 End: 02/28/14 Due: 02/28/15

Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03170284 Org: User:
Start: 06/17/08 End: 08/01/12 Due: 08/01/13

A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01392716 Org: User:
Start: 10/31/97 End: 02/28/06 Due: 02/28/07

A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01588990 Org: User:
Start: 06/26/12 End: 09/30/16 Due: 09/30/17

A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT03036501 Org: User:
Start: 01/03/17 End: 02/28/17 Due: 02/28/18

A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis

Phase: N/A Priority: Normal
NCT ID: NCT02115997 Org: User:
Start: 07/06/15 End: 06/07/22 Due: 06/07/23

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03875079 Org: User:
Start: 06/24/19 End: 07/14/22 Due: 07/14/23

A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.

Phase: N/A Priority: Normal
NCT ID: NCT00425438 Org: User:
Start: 03/31/07 End: 04/30/08 Due: 04/30/09

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Phase: N/A Priority: Normal
NCT ID: NCT00744367 Org: User:
Start: 10/31/08 End: 11/30/10 Due: 11/30/11

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

Phase: N/A Priority: Normal
NCT ID: NCT01326962 Org: User:
Start: 11/30/11 End: 05/12/13 Due: 05/12/14

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT00943826 Org: User:
Start: 06/29/09 End: 09/09/15 Due: 09/09/16

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02257567 Org: User:
Start: 10/15/14 End: 10/21/21 Due: 10/21/22

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00069108 Org: User:
Start: 07/31/03 End: 08/31/06 Due: 08/31/07

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Phase: N/A Priority: Normal
NCT ID: NCT00077766 Org: User:
Start: 03/31/04 End: 08/31/05 Due: 08/31/06

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis

Phase: N/A Priority: Normal
NCT ID: NCT02238080 Org: User:
Start: 12/31/09 End: 06/30/12 Due: 06/30/13

A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT00845832 Org: User:
Start: 03/31/09 End: 03/31/13 Due: 03/31/14

A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections

Phase: N/A Priority: Normal
NCT ID: NCT06369220 Org: User:
Start: 07/29/24 End: 07/30/25 Due: 07/30/26

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT02171429 Org: User:
Start: 11/14/14 End: 05/25/20 Due: 05/25/21

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Phase: N/A Priority: Normal
NCT ID: NCT02187861 Org: User:
Start: 12/01/14 End: 03/16/18 Due: 03/16/19

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05171647 Org: User:
Start: 04/25/22 End: 02/28/27 Due: 02/28/28

A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection

Phase: N/A Priority: Normal
NCT ID: NCT00192647 Org: User:
Start: 08/31/04 End: 03/31/09 Due: 03/31/10

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Phase: N/A Priority: Normal
NCT ID: NCT01765543 Org: User:
Start: 07/31/13 End: 11/30/15 Due: 11/30/16

A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.

Phase: N/A Priority: Normal
NCT ID: NCT02091414 Org: User:
Start: 08/31/06 End: 02/28/09 Due: 02/28/10